Measles, mumps and rubella outbreaks still represent an healthcare issue, even though major advancements have been done towards their eradication. A poor inclination towards Mmr (measles-mumps-rubella) vaccination may constitute a major cause of increased risk to contract one of these diseases amongst specific population groups like migrants, alternative medicine users, some religious groups, healthcare professionals.
Information on Mmr vaccines coverage amongst these and others “hard-to-reach” groups was included in a document made and published Ecdc in range of the European project Venice II (Vaccine European New Integrated Collaboration Effort II). Main aim of the document was to provide a complete review of measles, mumps and rubella focuses which have been reported in the last twenty years in Europe.
An update on Mmr
Primary tabs
Autori:
Sezioni:
Indice:
Vaccination
prossimo articolo
Seventh Framework Programme: data on Italian participation
Research and development expenditure in Italy amounts to approximately 17.53 billion euro.
The proportion of GDP devoted to R&D is 1.18%, which is lower than the European average standing at around 1.8% and higher only compared to countries such as Hungary, Poland and Greece. Trying to compensate for the scarce resources that governments have devoted and continue to devote to research, Italian researchers seek to obtain funds through the several funding options provided by the European Community.